nicotine dose (33% at the low dose vs. 10% at the high dose), while high dependence individuals had greater abstinence rates at the higher nicotine dose (9% at the low dose vs. 22% at the high dose). This study suggests that the use of genetic information, in combination with assessment of the degree of physiological dependence, may greatly increase the effectiveness of nicotine cessation treatments. Furthermore, analysis of clinical trial data has indicated that the use of genetic information may enhance statistical power and reduce costs of nicotine cessation clinical trials (G. R. Uhl, Drgon, Johnson, & Rose, 2009).
